Please login first
Victor Nizet   Professor  Senior Scientist or Principal Investigator 
Timeline See timeline
Victor Nizet published an article in March 2019.
Top co-authors See all
Robin D Knight

739 shared publications

UCSD School of Medicine

Ze'ev Ronai

696 shared publications

Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037

Christian Ottensmeier

416 shared publications

Cancer Sciences Division, Faculty of Medicine, University of Southampton, UK

Marc E. Rothenberg

399 shared publications

Division of Allergy and Immunology

Bernhard Ø. Palsson

365 shared publications

Department of Bioengineering, University of California, San Diego, United States

Publication Record
Distribution of Articles published per year 
(1997 - 2018)
Total number of journals
published in
Publications See all
Article 0 Reads 0 Citations Clinical Data on Daptomycin Plus Ceftaroline Versus Standard of Care Monotherapy in the Treatment of Methicillin-Resista... Matthew Geriak, Fadi Haddad, Khulood Rizvi, Warren Rose, Rav... Published: 11 March 2019
Antimicrobial Agents and Chemotherapy, doi: 10.1128/aac.02483-18
DOI See at publisher website ABS Show/hide abstract
Vancomycin (VAN) and daptomycin (DAP) are approved as monotherapy for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. A regimen of daptomycin plus ceftaroline (DAP+CPT) has shown promise in published case series of MRSA salvage therapy, but no comparative data exist to compare up front DAP+CPT head-to-head vs. standard monotherapy as initial treatment. In a pilot study, we evaluated 40 adult patients who were randomized to receive DAP 6-8 mg/kg/d + CPT 600 mg IV q8 h (n=17) or standard monotherapy (n=23) with vancomycin (VAN, dosed to achieve serum trough concentrations 15-20 mg/L, n=21) or DAP 6-8 mg/kg/d (n=2). Serum drawn on the first day of bacteremia was sent to a reference laboratory post-hoc for measurement of IL-10 concentrations and correlation to in-hospital mortality. Sources of bacteremia, median Pitt bacteremia scores, Charlson comorbidity indices, and median serum IL-10 serum concentrations were similar in both groups. Although the study was initially designed to examine bacteremia duration, we observed an unanticipated in-hospital mortality difference of 0% (0/17) for combination and 26% (6/23) for monotherapy (P=0.029), causing us to halt the study. Among patients with IL-10 > 5 pg/mL, 0% (0/14) died in the DAP+CPT group vs. 26% (5/19) in the monotherapy group (P=0.057). Here we share the full results of this preliminary (but aborted) assessment of early DAP+CPT versus standard monotherapy in MRSA bacteremia, hoping to encourage a more definitive clinical trial of its potential benefits against this leading cause of infection associated mortality.
Article 0 Reads 0 Citations Docking simulation and antibiotic discovery targeting the MlaC protein in Gram-negative bacteria Yu-Ming M. Huang, Jason Munguia, Yinglong Miao, Victor Nizet... Published: 19 February 2019
Chemical Biology & Drug Design, doi: 10.1111/cbdd.13462
DOI See at publisher website
Article 0 Reads 0 Citations Recurrent group A Streptococcus tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberran... Jennifer M. Dan, Colin Havenar-Daughton, Kayla Kendric, Rita... Published: 06 February 2019
Science Translational Medicine, doi: 10.1126/scitranslmed.aau3776
DOI See at publisher website ABS Show/hide abstract
“Strep throat” is highly prevalent among children, yet it is unknown why only some children develop recurrent tonsillitis (RT), a common indication for tonsillectomy. To gain insights into this classic childhood disease, we performed phenotypic, genotypic, and functional studies on pediatric group A Streptococcus (GAS) RT and non-RT tonsils from two independent cohorts. GAS RT tonsils had smaller germinal centers, with an underrepresentation of GAS-specific CD4+ germinal center T follicular helper (GC-TFH) cells. RT children exhibited reduced antibody responses to an important GAS virulence factor, streptococcal pyrogenic exotoxin A (SpeA). Risk and protective human leukocyte antigen (HLA) class II alleles for RT were identified. Lastly, SpeA induced granzyme B production in GC-TFH cells from RT tonsils with the capacity to kill B cells and the potential to hobble the germinal center response. These observations suggest that RT is a multifactorial disease and that contributors to RT susceptibility include HLA class II differences, aberrant SpeA-activated GC-TFH cells, and lower SpeA antibody titers.
Article 0 Reads 0 Citations To NET or not to NET:current opinions and state of the science regarding the formation of neutrophil extracellular traps Sebastian Boeltz, Poorya Amini, Hans-Joachim Anders, Felipe ... Published: 08 January 2019
Cell Death & Differentiation, doi: 10.1038/s41418-018-0261-x
DOI See at publisher website
Article 0 Reads 0 Citations Enhanced topical delivery of non-complexed molecular iodine for Methicillin-resistant Staphylococcus aureus decolonizati... Satoshi Uchiyama, Samira Dahesh, Victor Nizet, Jack Kessler Published: 01 January 2019
International Journal of Pharmaceutics, doi: 10.1016/j.ijpharm.2018.11.004
DOI See at publisher website
Article 0 Reads 0 Citations Pharmacological Targeting of Pore-Forming Toxins as Adjunctive Therapy for Invasive Bacterial Infection Tamara Escajadillo, Victor Nizet Published: 17 December 2018
Toxins, doi: 10.3390/toxins10120542
DOI See at publisher website PubMed View at PubMed ABS Show/hide abstract
For many of the most important human bacterial infections, invasive disease severity is fueled by the cell damaging and pro-inflammatory effects of secreted pore-forming toxins (PFTs). Isogenic PFT-knockout mutants, e.g., Staphylococcus aureus lacking α-toxin or Streptococcus pneumoniae deficient in pneumolysin, show attenuation in animal infection models. This knowledge has inspired multi-model investigations of strategies to neutralize PFTs or counteract their toxicity as a novel pharmacological approach to ameliorate disease pathogenesis in clinical disease. Promising examples of small molecule, antibody or nanotherapeutic drug candidates that directly bind and neutralize PFTs, block their oligomerization or membrane receptor interactions, plug establishment membrane pores, or boost host cell resiliency to withstand PFT action have emerged. The present review highlights these new concepts, with a special focus on β-PFTs produced by leading invasive human Gram-positive bacterial pathogens. Such anti-virulence therapies could be applied as an adjunctive therapy to antibiotic-sensitive and -resistant strains alike, and further could be free of deleterious effects that deplete the normal microflora.